BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:tilrekimig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of tilrekimig\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07792941-1455@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:tilrekimig: Phase 1 readout est. (NCT07792941)
DESCRIPTION:tilrekimig\, phase 1.\nStudy: A Study to Learn About the Single
  Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adul
 ts When Co-Mixed With rHuPH20\nEstimated primary completion: 20 February 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tilrekimig#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07792941
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06977581-1455@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:tilrekimig: Phase 2 readout est. (NCT06977581)
DESCRIPTION:tilrekimig\, phase 2\, Asthma.\nStudy: A Study to Learn About t
 he Study Medicine Called PF-07275315 in People With Moderate-To-Severe Ast
 hma\nEstimated primary completion: 8 March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tilrekimig#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06977581
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07765888-1455@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20280310
DTEND;VALUE=DATE:20280311
SUMMARY:tilrekimig: Phase 3 readout est. (NCT07765888)
DESCRIPTION:tilrekimig\, phase 3\, Atopic Dermatitis.\nStudy: A Study to Le
 arn About the Study Medicine Called Tilrekimig in People With Moderate-to-
 Severe Eczema\nEstimated primary completion: 10 March 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tilrekimig#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07765888
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783425-1455@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20280908
DTEND;VALUE=DATE:20280909
SUMMARY:tilrekimig: Phase 3 readout est. (NCT07783425)
DESCRIPTION:tilrekimig\, phase 3\, Atopic Dermatitis.\nStudy: A Study to Le
 arn About the Study Medicine Called Tilrekimig in People With Moderate-to 
 Severe Eczema\nEstimated primary completion: 8 September 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tilrekimig#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07783425
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772921-1455@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:tilrekimig: Phase 3 readout est. (NCT07772921)
DESCRIPTION:tilrekimig\, phase 3\, Asthma.\nStudy: A Study to Learn About t
 he Study Medicine Called Tilrekimig in People With Severe Asthma\nEstimate
 d primary completion: 1 June 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tilrekimig#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07772921
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07869043-1455@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20290607
DTEND;VALUE=DATE:20290608
SUMMARY:tilrekimig: Phase 3 readout est. (NCT07869043)
DESCRIPTION:tilrekimig\, phase 3\, Asthma.\nStudy: A Study to Learn About t
 he Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe A
 sthma\nEstimated primary completion: 7 June 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/tilrekimig#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07869043
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363694-1455@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20301024
DTEND;VALUE=DATE:20301025
SUMMARY:tilrekimig: Phase 2/3 readout est. (NCT07363694)
DESCRIPTION:tilrekimig\, phase 2/3\, Chronic Obstructive Pulmonary Disease.
 \nStudy: A Study to Learn About the Study Medicine Called PF-07275315 in P
 eople With Moderate to Severe Chronic Obstructive Pulmonary Disease\nEstim
 ated primary completion: 24 October 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tilrekimig#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07363694
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07839884-1455@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20340421
DTEND;VALUE=DATE:20340422
SUMMARY:tilrekimig: Phase 3 readout est. (NCT07839884)
DESCRIPTION:tilrekimig\, phase 3\, Chronic Obstructive Pulmonary Disease.\n
 Study: A Continuation Study of Tilrekimig in Adults With Moderate-to-Sever
 e Long-Term Breathing Difficulty\, Known by the Medical Term of Chronic Ob
 structive Pulmonary Disease (COPD) to Learn About This Medicine When Used 
 for a Long Period of Time\nEstimated primary completion: 21 April 2034. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tilrekimig#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07839884
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
